Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLM033
MIFTS: 63

Pulmonary Embolism

Categories: Blood diseases, Cardiovascular diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Pulmonary Embolism

About this section

MalaCards integrated aliases for Pulmonary Embolism:

Name: Pulmonary Embolism 12 29 55 43 3 44 15 63 73
Pulmonary Embolus 12 15
Pulmonary Artery Embolism 12

Classifications:

MalaCards categories:
Anatomical: Cardiovascular diseases Respiratory diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:9477
MeSH 44 D011655
NCIt 50 C50713
SNOMED-CT 68 59282003
UMLS 73 C0034065
Sources

Summaries for Pulmonary Embolism

About this section
MedlinePlus : 43 What is a pulmonary embolism (PE)? A pulmonary embolism (PE) is a sudden blockage in a lung artery. It usually happens when a when a blood clot breaks loose and travels through the bloodstream to the lungs. PE is a serious condition that can cause Permanent damage to the lungs Low oxygen levels in your blood Damage to other organs in your body from not getting enough oxygen PE can be life-threatening, especially if a clot is large, or if there are many clots. Who gets a pulmonary embolism (PE)? Anyone can get a pulmonary embolism (PE), but certain things can raise your risk of PE: Having surgery, especially joint replacement surgery Certain medical conditions, including Cancers Heart diseases Lung diseases A broken hip or leg bone or other trauma Hormone-based medicines, such as birth control pills or hormone replacement therapy Pregnancy and childbirth. The risk is highest for about six weeks after childbirth. Not moving for long periods, such as being on bed rest, having a cast, or taking a long plane flight Age. Your risk increases as you get older, especially after age 40. Family history and genetics. Certain genetic changes that can increase your risk of blood clots and PE. Obesity What causes a pulmonary embolism (PE)? The cause is usually a blood clot in the leg called a deep vein thrombosis that breaks loose and travels through the bloodstream to the lung. What are the symptoms of a pulmonary embolism (PE)? Half the people who have pulmonary embolism have no symptoms. If you do have symptoms, they can include shortness of breath, chest pain or coughing up blood. Symptoms of a blood clot include warmth, swelling, pain, tenderness and redness of the leg. What are the treatments for a pulmonary embolism (PE)? The goal of treatment is to break up clots and help keep other clots from forming. NIH: National Heart, Lung, and Blood Institute

MalaCards based summary : Pulmonary Embolism, also known as pulmonary embolus, is related to chronic thromboembolic pulmonary hypertension and respiratory failure, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Pulmonary Embolism is PLAT (Plasminogen Activator, Tissue Type), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Warfarin and Heparin have been mentioned in the context of this disorder. Affiliated tissues include lung, heart and testes, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 An artery disease characterized by a blockage of the main artery of the lung or one of its branches by a substance that has travelled from elsewhere in the body, e.g. a blood clot.

CDC : 3 Venous thromboembolism (VTE), also known as blood clots, is an underdiagnosed and serious, but preventable medical condition. It is important to know about VTE because it can happen to anybody at any age and cause serious illness, disability, and in some cases, death. The good news is that VTE can be prevented and treated if discovered early.

PubMed Health : 63 About pulmonary embolism: Pulmonary embolism (PULL-mun-ary EM-bo-lizm), or PE, is a sudden blockage in a lung artery. The blockage usually is caused by a blood clot that travels to the lung from a vein in the leg.A clot that forms in one part of the body and travels in the bloodstream to another part of the body is called an embolus (EM-bo-lus).PE is a serious condition that can:

Wikipedia : 76 Pulmonary embolism (PE) is a blockage of an artery in the lungs by a substance that has moved from... more...

Sources

Related Diseases for Pulmonary Embolism

About this section

Diseases related to Pulmonary Embolism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 553)
# Related Disease Score Top Affiliating Genes
1 chronic thromboembolic pulmonary hypertension 32.8 CRP F2 NPPB
2 respiratory failure 32.4 ALB CRP F3
3 protein c deficiency 31.9 F2 F5 F9 MTHFR SERPINC1
4 antithrombin iii deficiency 31.8 APOH F10 F2 F5 MTHFR SERPINC1
5 thrombophilia due to thrombin defect 31.3 APOH F10 F2 F3 F5 MTHFR
6 pulmonary hypertension 30.8 F3 NPPB PLAT VWF
7 cardiac arrest 30.7 ALB NPPB TNNT2
8 inferior myocardial infarction 30.6 NPPB PLAT
9 patent foramen ovale 30.5 APOH F2 F5 MTHFR PLAT SERPINC1
10 heparin-induced thrombocytopenia 30.5 F10 F3 SERPINC1
11 cardiogenic shock 30.5 NPPB PLAT
12 inferior vena cava interruption 30.2 F5 MTHFR SERPINE1
13 acute cor pulmonale 30.1 NPPB PLAT SERPINE1 SERPINF2
14 pulmonary edema 30.1 CRP F2 NPPB
15 protein s deficiency 30.1 APOH F2 F3 F5 MTHFR SERPINC1
16 thrombocytosis 30.1 CRP F2 F3 SERPINC1
17 may-thurner syndrome 30.1 APOH F5
18 thrombophlebitis 30.0 APOH F2 F5 MTHFR PLAT SERPINC1
19 lemierre's syndrome 29.9 CRP F3 MTHFR SERPINE1
20 post-thrombotic syndrome 29.9 F2 F5 SERPINC1 SERPINE1
21 thrombasthenia 29.9 F2 F3 F5 MTHFR
22 cardiac tamponade 29.9 F2 F9 NPPB
23 atrial standstill 1 29.9 NPPB TNNI3 TNNT2
24 acute liver failure 29.9 ALB F2 F5
25 kwashiorkor 29.9 ALB F2
26 thrombophilia due to activated protein c resistance 29.8 APOH F10 F2 F3 F5 F9
27 sagittal sinus thrombosis 29.8 F2 F3 F5 SERPINC1
28 endocarditis 29.8 ALB APOH CRP F2 PLAT SERPINC1
29 coronary thrombosis 29.7 F3 PLAT SERPINC1 SERPINE1 VWF
30 thrombosis 29.7 APOH F10 F2 F3 F5 F9
31 atrial fibrillation 29.7 CRP F10 F2 NPPB PLAT VWF
32 infective endocarditis 29.7 APOH CRP F2 SERPINE1 TNNI3
33 sticky platelet syndrome 29.7 F5 SERPINC1 SERPINE1
34 budd-chiari syndrome 29.7 APOH F2 F3 F5 MTHFR SERPINC1
35 homocysteinemia 29.7 ALB CRP F2 F5 MTHFR SERPINC1
36 varicose veins 29.7 F2 F5 MTHFR SERPINC1 VWF
37 catastrophic antiphospholipid syndrome 29.6 APOH F3 F5 MTHFR SERPINE1
38 eclampsia 29.5 ALB F2 MTHFR SERPINC1
39 factor xi deficiency 29.5 F2 F3 F9 SERPINC1
40 buerger disease 29.5 APOH F2 MTHFR SERPINE1
41 portal vein thrombosis 29.4 APOH F2 F5 MTHFR SERPINC1 SERPINE1
42 vasculitis 29.4 APOH CRP VWF
43 chronic kidney failure 29.4 ALB CRP MTHFR NPPB
44 thrombotic thrombocytopenic purpura 29.4 APOH F3 VWF
45 essential thrombocythemia 29.4 F2 F3 SERPINE1 VWF
46 hemophilia 29.4 F2 F3 F9 VWF
47 acquired hemophilia 29.4 F10 F3 F5 F9
48 antiphospholipid syndrome 29.4 APOH F10 F2 F3 F5 MTHFR
49 marantic endocarditis 29.4 F2 F3 MTHFR PLAT SERPINC1 SERPINF2
50 factor vii deficiency 29.3 F10 F2 F3 F9

Graphical network of the top 20 diseases related to Pulmonary Embolism:



Diseases related to Pulmonary Embolism
Sources

Symptoms & Phenotypes for Pulmonary Embolism

About this section

UMLS symptoms related to Pulmonary Embolism:


hemoptysis, snoring, coughing

MGI Mouse Phenotypes related to Pulmonary Embolism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 CRP F10 F2 F3 F5 F9
2 homeostasis/metabolism MP:0005376 10.06 ALB APOH CRP F10 F2 F3
3 liver/biliary system MP:0005370 9.5 ALB F5 F9 FABP3 MTHFR SERPINC1
4 mortality/aging MP:0010768 9.5 ALB APOH F10 F2 F3 F5
Sources

Drugs & Therapeutics for Pulmonary Embolism

About this section

PubMedHealth treatment related to Pulmonary Embolism: 63

Pulmonary embolism (PE) is treated with medicines, procedures, and other therapies. The main goals of treating PE are to stop the blood clot from getting bigger and keep new clots from forming.Treatment may include medicines to thin the blood and slow its ability to clot. If your symptoms are life threatening, your doctor may give you medicine to quickly dissolve the clot. Rarely, your doctor may use surgery or another procedure to remove the clot.

Drugs for Pulmonary Embolism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 542)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 81-81-2 6691 54678486
2
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772 46507594
3
Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable
4
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6
5
Enoxaparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9005-49-6 772
6 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
8
Tranylcypromine Approved, Investigational Phase 4,Phase 3 155-09-9 441233
9
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 366789-02-8
10
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1197-18-8 5526
11 fluindione Approved, Investigational Phase 4,Phase 3 957-56-2
12
Phytonadione Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 84-80-0 4812 5284607
13
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
14
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
15
Nitric Oxide Approved Phase 4,Phase 2,Phase 1 10102-43-9 145068
16
Budesonide Approved Phase 4 51333-22-3 63006 5281004
17
Ipratropium Approved Phase 4 60205-81-4, 22254-24-6 43232
18
Terbutaline Approved Phase 4 23031-25-6 5403
19
Apixaban Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 503612-47-3 10182969
20
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 50-78-2 2244
21
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Not Applicable 113665-84-2, 120202-66-6 60606
22
Tinzaparin Approved Phase 4,Phase 2,Phase 3,Not Applicable 9005-49-6, 9041-08-1 25244225
23
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 616-91-1 12035
24
Phenprocoumon Approved, Investigational Phase 4,Phase 3 435-97-2 54680692 9908
25
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
26
Fondaparinux Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 104993-28-4
27
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 175805 71273
28
Furosemide Approved, Vet_approved Phase 4,Phase 3,Not Applicable 54-31-9 3440
29
Morphine Approved, Investigational Phase 4,Phase 3,Not Applicable 57-27-2 5288826
30
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Not Applicable 329-65-7 838
31
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 51-43-4 5816
32
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
33
Acenocoumarol Approved, Investigational Phase 4,Phase 3 152-72-7 9052 54676537
34
Streptokinase Approved, Investigational Phase 4,Not Applicable 9002-01-1
35
Epoprostenol Approved Phase 4 61849-14-7, 35121-78-9 5280427 5282411
36
Nitrous oxide Approved, Vet_approved Phase 4 10024-97-2 948
37
Pancrelipase Approved, Investigational Phase 4,Phase 3 53608-75-6
38
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
39
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1 103-90-2 1983
40
Desirudin Approved Phase 4,Phase 2,Phase 3 120993-53-5
41
Spironolactone Approved Phase 4,Phase 3 52-01-7, 1952-01-7 5833
42
Eplerenone Approved Phase 4,Phase 3 107724-20-9 443872 150310
43
Ibuprofen Approved Phase 4 15687-27-1 3672
44
Salicylic acid Approved, Investigational, Vet_approved Phase 4,Phase 3 69-72-7 338
45
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3 22916-47-8 4189
46 Edoxaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 480449-70-5
47
Metronidazole Approved Phase 4,Not Applicable 443-48-1 4173
48
Betrixaban Approved, Investigational Phase 4,Phase 3,Phase 2 330942-05-7
49
Polidocanol Approved Phase 4,Not Applicable 9002-92-0
50
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635

Interventional clinical trials:

(show top 50) (show all 1207)
# Name Status NCT ID Phase Drugs
1 Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy Unknown status NCT02979561 Phase 4 Dabigatran Etexilate;Warfarin
2 Home Treatment of Pulmonary Embolism Unknown status NCT00214929 Phase 4
3 Low Dose Rt-PA for Acute Normotensive Pulmonary Embolism With RVD Unknown status NCT01531829 Phase 4 Recombinant tissue plasminogen activator (rt-PA);Low Molecular Weight Heparin
4 Low Dose Prolonged Infusion of Tissue Type Plasminogen Activator Therapy in Massive Pulmonary Embolism Unknown status NCT02029456 Phase 4 25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours
5 Two Weeks of Low Molecular Weight Heparin for Distal Vein Thrombosis Unknown status NCT01252420 Phase 4 Enoxaparin
6 Comparison of Low-Molecular-Weight Heparin (LMWH) and Unfractionated Heparin (UFH) in Combination With Thrombolytic Treatment of Acute Massive Pulmonary Thromboembolism Unknown status NCT01956955 Phase 4 enoxaparin ,alteplase, unfractionated heparin
7 Comparison of Topical and Infusion Tranexamic Acid After Total Knee Arthroplasty Unknown status NCT02453802 Phase 4 Tranexamic Acid 5%,5ml/amp;Tranexamic Acid 5%,5ml/amp;rivaroxaban (10mg);0.9% Normal Saline;0.9% Normal Saline
8 Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation Unknown status NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
9 Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis Unknown status NCT00450645 Phase 4 low molecular weight heparin
10 Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients Unknown status NCT01610141 Phase 4
11 A Feasibility Study to Assess the Use of Gadolinium in Computed Tomography Unknown status NCT02163005 Phase 4 Gadolinium
12 Exhaled NO Based Treatment of Chronic Obstructive Pulmonary Disease (COPD), ICS/LABA Versus LAMA Unknown status NCT02546349 Phase 4 fluticasone/salmeterol, tiotropium
13 A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population Unknown status NCT02618382 Phase 4 Tranexamic Acid
14 Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis Unknown status NCT02959801 Phase 4
15 Efficacy of Nebulized Pulmicort Respules in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
16 Clinical and Economic Implications of Genetic Testing for Warfarin Management Unknown status NCT00964353 Phase 4 Warfarin
17 Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
18 A Safety and Efficacy Study for Implantation and Retrieval Procedures Using the VENATECH® Retrieval Filter System Unknown status NCT02674672 Phase 4
19 The Efficacy and Safety Study of Dabigatran and Warfarin to Non-valvular Atrial Fibrillation Patients Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
20 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
21 Reinflation After Early Tourniquet Release in Total Knee Arthroplasty Unknown status NCT01832272 Phase 4
22 Tranexamic Acid in Knee Joint Surgery Unknown status NCT02278263 Phase 4 Tranexamic Acid;Normal saline (0.9% NaCl)
23 Tranexamic Acid in Intertrochanteric and Subtrochanteric Femur Fractures Unknown status NCT02580227 Phase 4 Tranexamic Acid
24 Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism Completed NCT02132689 Phase 4 Actilyse (Thrombolytic therapy);Heparine (Standard anticoagulation therapy)
25 A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department Completed NCT02584660 Phase 4 Rivaroxaban;Standard-of-care
26 Tinzaparin in the Treatment of the Acute Pulmonary Embolism Completed NCT00711308 Phase 4 tinzaparin;acenocoumarol
27 Age-adjusted D-dimer Cut-off Levels to Rule Out Pulmonary Embolism Completed NCT01134068 Phase 4
28 Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism Completed NCT00442234 Phase 4 Monteplase
29 Deferment of Imaging for Pulmonary Embolism Completed NCT00381511 Phase 4 low molecular weight heparin
30 Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC) Completed NCT00968929 Phase 4 Recombinant Streptokinase;Urokinase
31 PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption Completed NCT00457158 Phase 4
32 Epoprostenol in Pulmonary Embolism Completed NCT01014156 Phase 4 epoprostenol
33 Protection From Pulmonary Embolism With the Permanent OptEaseâ„¢ Filter (PROOF) Completed NCT00233740 Phase 4
34 Detection of Pulmonary Embolism With CECT Completed NCT00351754 Phase 4 Isovue
35 NAC, NaHCO3 and NS Prophylaxis for CTPA in the ED on Suspicion of PE: A Randomized Controlled Trial Completed NCT02483143 Phase 4 NAC;NaHCO3;Normal Saline
36 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Completed NCT00365950 Phase 4 Duration of anticoagulation;Warfarin duration
37 Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin Completed NCT01729559 Phase 4 5000 Units unfractionated Heparin Q 8 hr;30mg enoxaparin Q12 hr
38 Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain Completed NCT01067456 Phase 4
39 D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Completed NCT00264277 Phase 4 Vitamin K antagonist (Coumarin anticoagulants)
40 The D-KAF (Dalteparin in Knee-to-Ankle Fracture) Trial Completed NCT00187408 Phase 4 Low Molecular Weight Heparin (dalteparin)
41 Study of IVC Filter Retrieval With the Günther Tulip Vena Cava Filter Completed NCT00196118 Phase 4
42 The Blood Saving Effect of Tranexamic Acid in Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis Completed NCT02458729 Phase 4 Tranexamic Acid 5%,5ml/amp (intraoperative);Tranexamic Acid 5%,5ml/amp (3 hours after operation);0.9% Normal Saline (intraoperative);0.9% Normal Saline (3 hours after operation);rivaroxaban (10mg)
43 Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer Completed NCT01989845 Phase 4 Rivaroxaban
44 Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis Completed NCT01245998 Phase 4 Dalteparin;Dalteparin
45 12-h and 2-h Urokinase Regimes of Pulmonary Thromboembolism in China Completed NCT00799968 Phase 4 Urokinase;Urokinase
46 Low Dosage of rt-PA in the Treatment of Pulmonary Thromboembolism in China Completed NCT00781378 Phase 4 rt-PA;rt-PA
47 The ENIGMA II Trial:Nitrous Oxide Anaesthesia and Cardiac Morbidity After Major Surgery: a Randomised Controlled Trial Completed NCT00430989 Phase 4 Nitrous Oxide;Nitrous Oxide
48 Comparison of Warfarin Dosing Using Decision Model Versus Pharmacogenetic Algorithm Completed NCT00511173 Phase 4
49 PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin) Completed NCT00077805 Phase 4 Enoxaparin sodium
50 Study to Find Out the Appropriate Initial Dose of the Anticoagulant Drug Phenprocoumon Completed NCT00586287 Phase 4 Phenprocoumon

Search NIH Clinical Center for Pulmonary Embolism

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: pulmonary embolism

Sources

Genetic Tests for Pulmonary Embolism

About this section

Genetic tests related to Pulmonary Embolism:

# Genetic test Affiliating Genes
1 Pulmonary Embolism 29
Sources

Anatomical Context for Pulmonary Embolism

About this section

MalaCards organs/tissues related to Pulmonary Embolism:

41
Lung, Heart, Testes, Bone, Brain, Liver, Endothelial
Sources

Publications for Pulmonary Embolism

About this section

Articles related to Pulmonary Embolism:

(show top 50) (show all 2826)
# Title Authors Year
1
Chronic pulmonary aspergillosis following pulmonary embolism. ( 30505676 )
2019
2
Ventilation/Perfusion SPECT Imaging-Diagnosing Other Cardiopulmonary Diseases Beyond Pulmonary Embolism. ( 30545516 )
2019
3
The electrocardiogram in pulmonary embolus: Diagnostic applications. ( 30509376 )
2019
4
Management of cardiac tamponade during catheter-directed thrombolysis of saddle pulmonary embolism: A clinical dilemma. ( 29970775 )
2018
5
Profile of pulmonary embolism in service personnel posted at high altitude area. ( 29961462 )
2018
6
Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study. ( 29934383 )
2018
7
Managing pulmonary embolism secondary to suppurative deep vein thrombophlebitis due to community-acquired <i>Staphylococcus aureus</i> in a resource-poor setting. ( 29943741 )
2018
8
Right-sided infective mural endocarditis complicated by septic pulmonary embolism and cardiac tamponade caused by MSSA. ( 29803298 )
2018
9
Pulmonary embolism and infarction with a paradoxical thrombus visualised in both atria. ( 29848540 )
2018
10
Prevalence of Pulmonary Embolism in Patients With Syncope. ( 29379959 )
2018
11
An unusual presentation of pulmonary embolism leading to infarction, cavitation, abscess formation and bronchopleural fistulation. ( 29437738 )
2018
12
Lesson of the month 2: Pulmonary embolism in a patient on rivaroxaban and concurrent carbamazepine. ( 29436450 )
2018
13
Utility of a Clinical Prediction Rule to Exclude Pulmonary Embolism Among Low-Risk Emergency Department Patients: Reason to PERC Up. ( 29450510 )
2018
14
Society of Interventional Radiology Position Statement on Catheter-Directed Therapy for Acute Pulmonary Embolism. ( 29422427 )
2018
15
Mesoaortic compression of a left-sided inferior vena-cava presenting as recurrent pulmonary embolism in a child-a novel anatomic thrombophilia? ( 29350462 )
2018
16
Pulmonary Embolism Among Patients With Acute Exacerbation Of Chronic Obstructive Pulmonary Disease: Implications For Emergency Medicine. ( 29945817 )
2018
17
A new method of CT for the cardiac measurement: correlation of computed tomography measured cardiac parameters and pulmonary obstruction index to assess cardiac morphological changes in acute pulmonary embolism patients. ( 29417409 )
2018
18
A case of Horner's syndrome after catheter-based fibrinolysis for pulmonary embolism. ( 29775165 )
2018
19
Ultrasound-Assisted Catheter-Directed Thrombolysis for Submassive Pulmonary Embolism. ( 29436310 )
2018
20
Half-Dose Versus Full-Dose Alteplase for Treatment of Pulmonary Embolism. ( 29979222 )
2018
21
Phlegmasia cerulea dolens presenting with acute compartment syndrome and pulmonary embolism. ( 29898911 )
2018
22
Acute Massive and Submassive Pulmonary Embolism: Preliminary Validation of Aspiration Mechanical Thrombectomy in Patients with Contraindications to Thrombolysis. ( 29980817 )
2018
23
Imaging for Pulmonary Embolism in Sickle Cell Disease: a 17-Year Experience. ( 29419477 )
2018
24
What's new in severe pulmonary embolism? ( 29947886 )
2018
25
Incidental pulmonary embolism in suspected stroke patients undergoing carotid CT angiography. ( 29426964 )
2018
26
Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature. ( 29976241 )
2018
27
Computed tomography pulmonary angiography is overused to diagnose pulmonary embolism in the emergency department of academic community hospital. ( 29441158 )
2018
28
A Clinically Meaningful Interpretation of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED) II and III Data. ( 29337091 )
2018
29
Optimizing Pulmonary Embolism Computed Tomography in the Age of Individualized Medicine: A Prospective Clinical Study. ( 29438139 )
2018
30
Recognition of unprovoked (idiopathic) pulmonary embolism-Prospective observational study. ( 29414454 )
2018
31
Clinical value of cardiac color ultrasound and cardiac troponin T combined with dynamic electrocardiogram in treatment of acute pulmonary embolism. ( 29434803 )
2018
32
Missed Massive Pulmonary Embolism and the Hidden Threat of a Distal Deep Vein Thrombosis. ( 29435465 )
2018
33
Bilateral pulmonary embolism after arthroscopic anterior cruciate ligament reconstruction: A case report. ( 29966950 )
2018
34
An enigmatic case presentation of Budd-Chiari syndrome with pulmonary embolism: An unusual syndrome with an uncommon complication. ( 29775966 )
2018
35
May-Thurner syndrome and the risk of pulmonary embolism in patients with acute deep venous thrombosis. ( 29909851 )
2018
36
Effect of the Pulmonary Embolism Rule-Out Criteria on Subsequent Thromboembolic Events Among Low-Risk Emergency Department Patients: The PROPER Randomized Clinical Trial. ( 29450523 )
2018
37
Outcomes of Pulmonary Embolectomy for Acute Pulmonary Embolism. ( 29952349 )
2018
38
Prognostic assessment for patients with cancer and incidental pulmonary embolism. ( 29445314 )
2018
39
Alcohol Consumption and the Risk of Incident Pulmonary Embolism in U.S. Women and Men. ( 29974610 )
2018
40
British Thoracic Society Guideline for the initial outpatient management of pulmonary embolism. ( 29955362 )
2018
41
Direct oral anticoagulant therapy as an alternative to surgery for the treatment of a patient with a floating thrombus in the ascending aorta and pulmonary embolism. ( 29942913 )
2018
42
Factor Xa inhibition and sPESI failure in intermediate-high-risk pulmonary embolism. ( 29958743 )
2018
43
Electrocardiographic changes in pulmonary embolism: Each lead could be a clue in solving the puzzle. ( 29933149 )
2018
44
Severe pulmonary embolism was secondary to cement inferior vena cava embolism after percutaneous vertebroplasty. ( 29428532 )
2018
45
Recurrent pulmonary embolism associated with deep venous thrombosis diagnosed as protein s deficiency owing to a novel mutation in PROS1: A case report. ( 29742732 )
2018
46
Deep venous thrombosis, pulmonary embolism and long-distance flights. ( 29948593 )
2018
47
Overuse and underuse of pulmonary CT angiography in patients with suspected pulmonary embolism. ( 29977871 )
2018
48
Therapeutic Anticoagulation for Pulmonary Embolism during First Trimester Surgical Abortion: Two Case Reports. ( 29428851 )
2018
49
Cement pulmonary embolism as a complication of percutaneous vertebroplasty in cancer patients. ( 29422089 )
2018
50
A Misguided Contraindication: International Normalized Ratio in Acute Liver Failure Precluding Thrombolysis for Massive Pulmonary Embolism: A Case Report. ( 30052530 )
2018
Sources

Variations for Pulmonary Embolism

About this section
Sources

Expression for Pulmonary Embolism

About this section
Search GEO for disease gene expression data for Pulmonary Embolism.
Sources

Pathways for Pulmonary Embolism

About this section

Pathways related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.01 ALB APOH F10 F2 F3 F5
2
Collagen chain trimerization 66
Show member pathways
 12.6 F10 F2 F3 F5 F9 SERPINC1
3
Selenium Micronutrient Network 1
Show member pathways
 12.07 ALB CRP F2 MTHFR PLAT SERPINE1
4
Complement and coagulation cascades 1 37
11.8 F10 F2 F3 F5 F9 PLAT
5
Gamma carboxylation, hypusine formation and arylsulfatase activation 66
Show member pathways
 11.64 F10 F2 F9
6
Formation of Fibrin Clot (Clotting Cascade) 66
Show member pathways
 11.52 F10 F2 F3 F5 F9 PLAT
7
Warfarin Pathway, Pharmacodynamics 61
10.72 F10 F2 F9
8
Dissolution of Fibrin Clot 66
10.61 PLAT SERPINE1 SERPINF2
Sources

GO Terms for Pulmonary Embolism

About this section

Cellular components related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum lumen GO:0005788 9.8 ALB F10 F2 F5 F9 SERPINC1
2 extracellular region GO:0005576 9.8 ALB APOH CRP F10 F2 F3
3 blood microparticle GO:0072562 9.73 ALB F2 SERPINC1 SERPINF2
4 collagen-containing extracellular matrix GO:0062023 9.7 APOH F3 PLAT SERPINC1 SERPINE1 SERPINF2
5 Golgi lumen GO:0005796 9.69 F10 F2 F9
6 platelet alpha granule lumen GO:0031093 9.65 ALB F5 SERPINE1 SERPINF2 VWF
7 platelet alpha granule GO:0031091 9.52 F5 VWF
8 troponin complex GO:0005861 9.49 TNNI3 TNNT2
9 cardiac myofibril GO:0097512 9.48 TNNI3 TNNT2
10 extracellular space GO:0005615 9.47 ALB APOH CRP F10 F2 F3
11 intrinsic component of external side of plasma membrane GO:0031233 9.46 F10 F3
12 cardiac Troponin complex GO:1990584 9.4 TNNI3 TNNT2
13 extracellular exosome GO:0070062 10.07 ALB APOH F2 F9 FABP3 PLAT

Biological processes related to Pulmonary Embolism according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.83 ALB F2 F5 SERPINC1
2 ER to Golgi vesicle-mediated transport GO:0006888 9.81 F10 F2 F5 F9
3 negative regulation of peptidase activity GO:0010466 9.74 SERPINC1 SERPINE1 SERPINF2
4 platelet degranulation GO:0002576 9.73 ALB APOH F5 SERPINE1 SERPINF2 VWF
5 fibrinolysis GO:0042730 9.67 F2 PLAT SERPINE1 SERPINF2
6 acute-phase response GO:0006953 9.63 CRP F2 SERPINF2
7 blood coagulation, intrinsic pathway GO:0007597 9.62 APOH F2 F9 VWF
8 positive regulation of blood coagulation GO:0030194 9.61 APOH F2 SERPINE1
9 regulation of muscle contraction GO:0006937 9.58 TNNI3 TNNT2
10 regulation of blood coagulation GO:0030193 9.58 APOH F2 SERPINC1
11 negative regulation of blood coagulation GO:0030195 9.56 APOH SERPINE1
12 blood coagulation GO:0007596 9.56 F10 F2 F3 F5 F9 PLAT
13 negative regulation of ATPase activity GO:0032780 9.55 TNNI3 TNNT2
14 plasminogen activation GO:0031639 9.54 APOH PLAT
15 negative regulation of plasminogen activation GO:0010757 9.49 SERPINE1 SERPINF2
16 blood coagulation, extrinsic pathway GO:0007598 9.48 F10 F3
17 negative regulation of fibrinolysis GO:0051918 9.46 APOH F2 SERPINE1 SERPINF2
18 hemostasis GO:0007599 9.17 F10 F2 F3 F5 F9 SERPINC1

Molecular functions related to Pulmonary Embolism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 ALB APOH CRP F10 F2 F3
2 serine-type peptidase activity GO:0008236 9.62 F10 F2 F9 PLAT
3 peptidase inhibitor activity GO:0030414 9.61 SERPINC1 SERPINE1 SERPINF2
4 phospholipid binding GO:0005543 9.58 APOH F10 F3
5 serine-type endopeptidase activity GO:0004252 9.55 F10 F2 F3 F9 PLAT
6 serine-type endopeptidase inhibitor activity GO:0004867 9.54 SERPINC1 SERPINE1 SERPINF2
7 troponin C binding GO:0030172 9.26 TNNI3 TNNT2
8 protease binding GO:0002020 9.02 F3 SERPINC1 SERPINE1 SERPINF2 VWF
Sources

Sources for Pulmonary Embolism

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z